Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.63% | 33.66% | 15.37% | -58.18% | -0.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.17% | 234.25% | 113.04% | -9.67% | 106.61% |
| Operating Income | -39.17% | -234.25% | -113.04% | 9.67% | -106.61% |
| Income Before Tax | -39.01% | -231.95% | -110.70% | 10.09% | -111.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.39% | -246.44% | -110.70% | 10.09% | -111.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.39% | -246.44% | -110.70% | 10.09% | -111.00% |
| EBIT | -39.17% | -234.25% | -113.04% | 9.67% | -106.61% |
| EBITDA | -39.16% | -234.45% | -113.09% | 9.71% | -106.68% |
| EPS Basic | 9.80% | -18.84% | 78.12% | 85.87% | 65.88% |
| Normalized Basic EPS | 11.31% | -12.72% | 78.12% | 85.87% | 65.88% |
| EPS Diluted | 9.80% | -18.84% | 78.12% | 85.87% | 65.88% |
| Normalized Diluted EPS | 11.31% | -12.72% | 78.12% | 85.87% | 65.88% |
| Average Basic Shares Outstanding | 56.75% | 191.52% | 863.08% | 536.47% | 518.40% |
| Average Diluted Shares Outstanding | 56.75% | 191.52% | 863.08% | 536.47% | 518.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |